合同(tong)(tong)研(yan)究、開(kai)發和(he)生產服(fu)務(wu)公司藥明生物發布其(qi)截至(zhi)2024年12月31日之經審核(he)年度業績。收益(yi)同(tong)(tong)比增長9.6%至(zhi)人(ren)民幣186.8億(yi)元，非新冠收益(yi)同(tong)(tong)比增長13.1%。經調整(zheng)(zheng)EBITDA同(tong)(tong)比增長14.4%至(zhi)人(ren)民幣80.0億(yi)元，經調整(zheng)(zheng)純利同(tong)(tong)比增長9.0%至(zhi)人(ren)民幣54.0億(yi)元（美通社(she)）
